Silberstein SD, Merriam GR: Sex hormones and headache
. J Pain Symptom Manage
Lipton RB, Stewart WF, Diamond S, et al.
: Prevalence and burden of migraine in the United States: data from the American Migraine Study II
Bille BS: Migraine in school children. A study of the incidence and short-term prognosis, and a clinical, psychological and electroencephalographic comparison between children with migraine and matched controls. Acta Paediatr 1962, 51(suppl 136):1–151.
Waters WE: Epidemiology of headache and migraine in women
. J Neurol Neurosurg Psychiatry
Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors
Epstein MT, Hockaday JM, Hockaday TD: Migraine and reporoductive hormones throughout the menstrual cycle
Neri I, Granella F, Nappi R, et al.
: Characteristics of headache at menopause: a clinico-epidemiologic study
Lay CL, Newman LC: Menstrual migraine: approaches to management
. CNS Drugs
Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24 (suppl 1):9–160.
Edelson RN: Menstrual migraine and other hormonal aspects of migraine
Couturier EG, Bomhof MA, Neven AK, van Duijn NP: Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment
Stewart WF, Lipton RB, Chee E, et al.
: Menstrual cycle and headache in a population sample of migraineurs
Schoenen J, Sawyer J: Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy
Salonen R, Saiers J: Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analysis
Silberstein SD, Massiou H, Le Jeunne C, et al.
: Rizatriptan in the treatment of menstrual migraine
. Obstet Gynecol
Loder E: Prophylaxis of menstrual migraine with triptans: problems and possibilities
:1677–1681. This is a well-considered discussion of pitfalls and possibilities associated with daily use of triptans in migraine management.PubMed
Paiva T, Farinha A, Martins A, et al.
: Chronic headaches and sleep disorders
. Arch Intern Med
Baker FC, Driver HS: Self-reported sleep across the menstrual cycle in young, healthy women
. J Psychosom Res
Hollander LE, Freeman EW, Sammel MD, et al.
: M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women
. Obstet Gynecol
Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. The American Academy of Neurology. Available at: http://www.ahsnet.org/guidelines.php. Accessed June, 2004. This website provides the Review of American Academy of Neurology guidelines for acute treatment of migraine.
Lipton RB, Stewart WF, Ryan RE Jr, et al.
: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials
. Arch Neurol Feb
Silberstein SD, Lipton RB, Goadsby PJ, eds: Headache in Clinical Practice. Oxford: ISIS Medical Media; 1998
Silberstein S, Tepper S, Brandes J, et al.
: Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine
Rapoport AM, Sheftell FD: Headache Disorders: A management Guide for Practitioners. Philadelphia: WB Saunders Company; 1996.
Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD: The triptan formulations: how to match patients and products
. CNS Drugs
Axert [prescribing information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc.; 2003
Imitrex [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2004
Zomig [prescribing information]. Wilmington, DE: Astra-Zeneca Pharmaceuticals; 2003
Maxalt [prescribing information]. Whitehouse Station, NJ: Merck & Co.,Inc; 2003.
Frova [prescribing information]. Craigavon, United Kingdom: Galen, Limited; 2001.
Amerge [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2003
Relpax [prescribing information]. New York, NY: Pfizer; 2003.
Nett R, Landy S, Shackelford S, Richardson MS, et al.
: Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine
. Obstet Gynecol
:835–842. This is a prospective study of oral sumatriptan in migraine management.PubMedCrossRef
Silberstein S: The efficacy of zolmitriptan is unaffected by the relationship to menses. Paper presented at the 10th Congress of the International Headache Society. New York, NY; June 20–July 2, 2001.
Loder E, Silberstein SD, Abu-Shakra S, et al.
: Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study
:120–130. This is a prospective study of efficacy and tolerability of oral zolmitriptan in migraine management.PubMedCrossRef
Massiou H, Silberstein S, Le Jeunne C, et al.: Efficacy of rizatriptan in menstrual migraine: Freedom from pain and associated symptoms at 2-h and 24-h sustained pain-free status. Cephalalgia 2000, 20:343–344.
Silberstein SD, Massiou H, McCarroll KA, Lines CR: Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data
MacGregor EA, Keywood C: Frovatriptan is effective in menstrually associated migraine (abstract)
Hettiarachi J, Pitei D: Oral Eletriptan is effective in treating menstrually-associated migraine and women on oral contraceptives or hormone replacement therapy. Paper presented at: 42nd Meeting of the American Headache Society. Montreal, Canada; 2002.
Sances G, Martignoni E, Fioroni L, et al.
: Naproxen sodium in menstrual migraine prophylaxis: a doubleblind placebo controlled study
Von Seggern RL, Mannix LK, Adelman JU: Rofecoxib in the prevention of perimenstrual migraine: an openlabel pilot trial
Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine
Newman LC, Mannix LK, Sandy S, et al.
: Naratriptan as short-term prophylaxis of menstrually-associated migraine: A randomized, double-blind, placebo-controlled study
:248–256. This is a prospective study of the use of naratriptan in shortterm prophylaxis of migraine management.PubMedCrossRef
Brandes JL, Smith T: Naratriptan 1 mg BID in the prophylactic treatment of menstrually-associated migraine. Paper presented at the 44th Annual Meeting of the American Headache Society. Seattle, WA; June 18–22, 2002.
Savani N, Loftus J, Mansbach H, Scot A: A randomised, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Paper presented at the 6th European Headache Congress. Istanbul, Turkey; June 17–22, 2002.
Nett R, Mannix L, Sandy S, et al.: Randomized, doubleblind, placebo-controlled parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Paper presented at the 55th Annual Meeting of the American Academy of Neurology. Honolulu, HI; March 29–April 5, 2003.
Silberstein SD, Elkind AH, Schreiber C: Frovatriptan, a selective HT1B/1D agonist, is effective for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60(Suppl 1):A94.
Smith T, Nett R: Frovatriptan is well tolerated during repeated use for prophylaxis of menstrually associated migraine (abstract). Headache 2003, 43:586.
Spierings ELH, Couch R, Blumenthal HJ: Clinical characteristics of menstrually associated migraine: a review of results from a study of the use of frovatriptan for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60(suppl 1):A493.
Tepper S, Freitag F: Prophylactic use of frovatriptan for menstrually associated migraine is effective and does not cause rebound migraine in the postdosing period (abstract)
Goldstein J, Ninan M, Rapoport AM: The safety and tolerability of frovatriptan, a selective 5HT1B/1D agonist, used for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60 (Suppl 1):A494.
Singer R, Schim J: Frovatriptan for prophylaxis of menstrually associated migraine: efficacy and tolerability in patients using oral contraceptives compared to nonusers (abstract). Headache 2003, 43:587.
Calhoun A: Four hypotheses for understanding menstrual migraine. The Female Patient 2004, 29:38–44. This is a comprehensive current review of the theories about menstrual migraine and their relevance to clinical management of these headaches.
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study
Petitti DB, Sidney S, Bernstein A, et al.
: Stroke in users of low-dose oral contraceptives
. N Engl J Med
Chan WS, Ray J, Wai EK, et al.
: Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence
. Arch Intern Med
Calhoun AH: Migraine and menopause
Facchinetti F, Sances G, Borella P, et al.
: Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium